JP2014532643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532643A5 JP2014532643A5 JP2014538819A JP2014538819A JP2014532643A5 JP 2014532643 A5 JP2014532643 A5 JP 2014532643A5 JP 2014538819 A JP2014538819 A JP 2014538819A JP 2014538819 A JP2014538819 A JP 2014538819A JP 2014532643 A5 JP2014532643 A5 JP 2014532643A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- group
- day
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 206010002022 amyloidosis Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 208000032859 Synucleinopathies Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 4
- 230000035508 accumulation Effects 0.000 claims 4
- 102000003802 alpha-Synuclein Human genes 0.000 claims 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 230000008021 deposition Effects 0.000 claims 4
- 230000002688 persistence Effects 0.000 claims 3
- 208000023769 AA amyloidosis Diseases 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SALAKVXYOKYXGW-UHFFFAOYSA-N CN(C(c1c(N2Cc(cc3O)ccc3O)nc[n]1Cc(cc1O)ccc1O)=O)C2=O Chemical compound CN(C(c1c(N2Cc(cc3O)ccc3O)nc[n]1Cc(cc1O)ccc1O)=O)C2=O SALAKVXYOKYXGW-UHFFFAOYSA-N 0.000 description 1
- PAVXNTKQTHLYGS-UHFFFAOYSA-N CN(c1c(C(N2Cc(cc3)cc(O)c3O)=O)[n](Cc(cc3)cc(O)c3O)cn1)C2=O Chemical compound CN(c1c(C(N2Cc(cc3)cc(O)c3O)=O)[n](Cc(cc3)cc(O)c3O)cn1)C2=O PAVXNTKQTHLYGS-UHFFFAOYSA-N 0.000 description 1
- PTJIKGVDIGNZKH-UHFFFAOYSA-N C[n]1c(C(N(CC(C2)C=CC(O)=C2O)C(N2Cc(cc3)cc(O)c3O)=O)=O)c2nc1 Chemical compound C[n]1c(C(N(CC(C2)C=CC(O)=C2O)C(N2Cc(cc3)cc(O)c3O)=O)=O)c2nc1 PTJIKGVDIGNZKH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552077P | 2011-10-27 | 2011-10-27 | |
| US61/552,077 | 2011-10-27 | ||
| PCT/US2012/059481 WO2013062762A1 (en) | 2011-10-27 | 2012-10-10 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532643A JP2014532643A (ja) | 2014-12-08 |
| JP2014532643A5 true JP2014532643A5 (https=) | 2015-12-03 |
| JP6095072B2 JP6095072B2 (ja) | 2017-03-15 |
Family
ID=48168320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538819A Expired - Fee Related JP6095072B2 (ja) | 2011-10-27 | 2012-10-10 | アミロイド病およびシヌクレイノパチーの処置のためのカフェイン含有化合物および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9169255B2 (https=) |
| EP (1) | EP2753333B1 (https=) |
| JP (1) | JP6095072B2 (https=) |
| CN (1) | CN104010641B (https=) |
| AU (1) | AU2012329274B2 (https=) |
| CA (1) | CA2853633A1 (https=) |
| WO (1) | WO2013062762A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001371B (zh) * | 2014-10-09 | 2019-07-05 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| NZ746901A (en) * | 2016-03-11 | 2023-06-30 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
| IL269550B2 (en) | 2017-03-27 | 2025-01-01 | Chase Therapeutics Corp | Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| CN113573708A (zh) * | 2019-02-07 | 2021-10-29 | 阿尔萨泰克公司 | 艾莫西平多价衍生物 |
| WO2023023867A1 (en) * | 2021-08-26 | 2023-03-02 | Mcmaster University | Compounds for reducing cholesterol and treating liver and kidney disease |
| CN115997722A (zh) * | 2022-12-26 | 2023-04-25 | 海南大学 | Aβ42-hIAPP共寡聚化物诱导的AD非人灵长类动物模型方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000069464A1 (en) * | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| EP1808169B8 (en) * | 1999-12-30 | 2012-07-04 | Proteotech Inc. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| DK1444233T3 (da) * | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| PT2527315E (pt) | 2002-05-31 | 2014-06-24 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
| CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
-
2012
- 2012-10-10 CA CA2853633A patent/CA2853633A1/en not_active Abandoned
- 2012-10-10 WO PCT/US2012/059481 patent/WO2013062762A1/en not_active Ceased
- 2012-10-10 AU AU2012329274A patent/AU2012329274B2/en not_active Ceased
- 2012-10-10 US US14/238,755 patent/US9169255B2/en not_active Expired - Fee Related
- 2012-10-10 CN CN201280051004.1A patent/CN104010641B/zh not_active Expired - Fee Related
- 2012-10-10 JP JP2014538819A patent/JP6095072B2/ja not_active Expired - Fee Related
- 2012-10-10 EP EP12842836.4A patent/EP2753333B1/en not_active Not-in-force